ASCO GU 2018: Overall Survival of Patients with Metastatic Prostate Cancer Starting ADT with Degarelix, A Gonadotropin-releasing Hormone Antagonist

San Francisco, CA ( Dr. Stephen Freedland and colleagues presented their results assessing overall survival (OS) among men with metastatic prostate cancer starting an ADT regimen with the gonadotropin-releasing hormone (GnRH) antagonist degarelix at today’s prostate cancer poster session at GU ASCO.

ASCO GU 2018: The Clinical Role of Germline and Somatic Genomics and the Risk-Stratification of Localized Prostate Cancer

San Francisco, CA ( Dr. Rob Bristow, previously at the Princess Margaret Cancer Centre, Toronto, Canada, is now at the University of Manchester as the Director of the Manchester Cancer Research Center. With an expertise in advanced prostate cancer, he is the invited keynote speaker. Today, he provided a tour-de-force review of the current literature focusing on germline and somatic mutational landscape in prostate cancer, specifically localized prostate cancer.

ASCO GU 2018: DNA Repair Gene Panel Mutations in Young Onset Prostate Cancer Cases in The United Kingdom

San Francisco, CA ( There is an increasing understanding and appreciation of the important role genetic predisposition plays in the development of prostate cancer (PCa), particularly in younger patients. While these are due both to common and rare germline variation, one particular focus has been in mutations in DNA damage response and repair pathways, such as BRCA-1 and BRCA-2.

ASCO GU 2018: Visceral Metastases on Abiraterone vs. Placebo: A Post-hoc Analysis of Mode of Radiographic Progression In COU-AA-302

San Francisco, CA ( Dr. Teply and colleagues presented a post-hoc analysis of COU-AA-302 [1] assessing mode of radiographic progression. Abiraterone prolongs survival in patients with prostate cancer due to its potent inhibition of androgen synthesis. Increased rates of visceral metastatic disease at the time of progression on abiraterone compared to baseline demonstrate a poor prognostic feature associated with non-AR dependent prostate cancer.

ASCO GU 2018: Occurrence of pathologic stage T3 disease at radical prostatectomy with ISUP grade group 1 (Gleason 3+3=6) prostate cancer.

San Francisco, CA ( In this study, the authors focus on outcomes in men with Gleason grade 1 (Gleason score 3+3=6) prostate cancer at the time of final pathology from radical prostatectomy specimens. With growing interest in how best to classify patients with Gleason Grade 1 disease, with some arguing that its clinical course deems it a benign tumor rather than true malignancy, the authors wanted to assess the clinical outcomes of this unique subset of men in their own institutional series.

ASCO GU 2018: Optimal Timing of Post-prostatectomy Radiotherapy For Prostate Cancer With High-risk Pathologic Features: A Multi-institutional Analysis

San Francisco, CA ( The standard of care for high-risk localized prostate cancer remains radical prostatectomy or radiotherapy + ADT. While ongoing studies are re-assessing the utility of neoadjuvant therapy prior radiotherapy or surgery, the standard of care remains unchanged. However, despite the primary modality of definitive therapy, biochemical recurrence in this high-risk population remains high (~50-70%), often necessitating multimodal therapy.

ASCO GU 2018: Evaluation of a Predefined as Threshold in a Large Cohort of Men with Localized Prostate Cancer

San Francisco, CA ( Recently, a clinical cell−cycle risk (CCR) score has been developed to include both molecular [cell cycle progression (CCP) RNA signature] and clinical [Cancer of the Prostate Risk Assessment (CAPRA)] features.1 Previous validations have demonstrated that this combined CCR score provides improved prognostic information relative to molecular or clinical features alone - in a cohort of men with NCCN-defined low-risk PCa, the CCP score improved clinical risk stratification of men who were at increased risk of BCR.2 As such, a CCR threshold score may help identify men with low−risk disease who may be candidates for active surveillance (AS).